News & Events

2022

November 29, 2022Suven Presenting Study Design,Initiation of Phase-3 Global Clinical Trial of Masupirdine (SUVN-502)View PDF
November 16, 2022Suven Life Sciences Limited Announces Randomization of First Patient in Phase-3 Global Clinical TriView PDF
November 11, 2022Suven Life Sciences presenting Pre-clinical and Clinical data of NCEs at Neuroscience (SFN) 2022View PDF
July 27, 2022Suven Life sciences schedule Poster Presentation at AAIC -2022View PDF
June 07, 2022SLSL presenting key Scientific & Baseline Characteristic Data of Samelisant (SUVN-G3031) Phase-2View PDF
April 01, 2022Clarification on Increase in volumeView PDF
April 01, 2022Clarification on Increase in volumeView PDF
March 17, 2022Suven presents two scientific posters on Masupirdine at AD/PD 2022 - Advances in Science & TherapyView PDF
March 16, 2022Suven selected to be part of the scientific program at the American Academy of Neurology 2022View PDF

2021

November 12, 2021Suven Life Sciences presented several scientific posters at Neuroscience-2021 virtual conferenceView PDF
November 08, 2021Suven Life Sciences Ltd to present two Scientific posters on Masupirdine at 2021 Clinical TrialsView PDF
October 11, 2021Clarification on Price MovementView PDF
August 16, 2021Suven Life sciences announces Phase 3 Clinical Trial of SUVN-502 (Masupirdine), a 5-HT6 antagonistView PDF
July 26, 2021Suven Life Sciences Ltd to present key Scientific Data at the Alzheimer’s Association InternationalView PDF
June 10, 2021SLEEP-2021 Virtual meeting - Suven e-poster presentationsView PDF

2020

December 28, 2020Clarification on Price MovementView PDF
December 28, 2020Clarification on Price MovementView PDF
December 28, 2020Clarification on Price MovementView PDF
August 27, 2020S L S announces five poster presentations including Phase-2 POC study design for SUVN-G3031View PDF
June 26, 2020Clarification on Price MovementView PDF
April 27, 2020Intimation of Fire Incidence at Jeedimetla unit in HyderabadView PDF
April 06, 2020Suven Life Sciences presented exploratory sub-group analyses data from Masupirdine (SUVN-502) PhaseView PDF
February 11, 2020Q3 & 9M FY20 Schedule of conference call for InvestorsView PDF

2019

December 19, 2019SUVEN receives EIR from US FDA for its Pashamylaram facilityView PDF
December 06, 2019Masupirdine (SUVN-502) Oral presentation at CTAD 2019 on 4 th December at San DiegoView PDF
November 30, 2019Suven Life Sciences announces Top-Line Results of SUVN-502 (Masupirdine) Phase 2A Study in PatientsView PDF
November 11, 2019Q2 & H1 FY20 Schedule of conference call for InvestorsView PDF
September 24, 2019First patient randomized in a Phase 2A, Proof of Concept (PoC) clinical trial of SUVN-G3031 for theView PDF
August 07, 2019Q1 FY20 Schedule of conference call for InvestorsView PDF
July 09, 2019Suven Life Sciences announces the delay in topline phase 2 study data of masupirdine (SUVN-502)View PDF
May 23, 2019Suven Life Sciences Ltd Announces the last patient last visit (LPLV) in their Phase 2 study of MasupView PDF
May 22, 2019Q4 and FY19 Schedule of conference call for InvestorsView PDF
April 22, 2019Suven completes the purchase of assets of Rising Pharmaceuticals through its joint venture partner,View PDF
April 13, 2019Suven receives court approval of “Stalking Horse” Agreement to buy the assets of Rising PharmaceuticView PDF
April 03, 2019Suven Life Sciences secures Product Patents in Israel, Japan, New Zealand and Sri LankaView PDF
March 29, 2019Suven Life Sciences secures Product Patents in Eurasia, Europe, South Korea and Sri LankaView PDF
March 08, 2019Suven announces the asset purchase agreement of Rising Pharmaceuticals through its joint venture parView PDF
February 05, 2019Suven Revenue up by 40.24%; PAT up by 40.27% for quarter ended December’ 2018View PDF
February 05, 2019Suven outcome of the Board MeetingView PDF
January 16, 2019Suven Life Sciences secures Product Patents in Australia and SingaporeView PDF